Literature DB >> 21153401

Pharmacokinetics and clinical predictors of surfactant redosing in respiratory distress syndrome.

Paola E Cogo1, Maddalena Facco, Manuela Simonato, Daniele De Luca, Francesca De Terlizi, Umberto Rizzotti, Giovanna Verlato, Maria Paola Bellagamba, Virgilio P Carnielli.   

Abstract

RATIONALE: Limited data are available on predictors for surfactant retreatment in preterm infants with respiratory distress syndrome (RDS).
OBJECTIVE: To study the pharmacokinetics of exogenous surfactant and the clinical parameters associated with surfactant redosing.
METHODS: Exogenous surfactant pharmacokinetics was studied in 125 preterm infants (birth weight 997 ± 432 g; gestational age 28.0 ± 2.6 weeks) with moderate to severe RDS requiring mechanical ventilation. Clinical and respiratory parameters were recorded hourly, and surfactant disaturated-phosphatidylcholine (DSPC) half-life, pool size, and endogenous synthesis were calculated by stable isotope tracing of surfactant DSPC isolated from serial tracheal aspirates. Univariate and multiple logistic regression were used to study the effects of clinical and surfactant kinetic variables on the need for redosing.
RESULTS: Fifty-three infants (42.4%) received one dose, 51 (40.8%) two doses, and 21 (16.8%) three doses. Median (interquartile range, IQR) DSPC half-life was 21 (13-39), 11 (7-17), and 10 (7-16) h after the first, second, and third dose, respectively (p = 0.07). Univariate analysis showed a significantly shorter DSPC half-life in infants requiring more surfactant doses. On logistic analysis, risk of redosing was higher with lower birth weight, worse radiological score, shorter DSPC half-life, and surfactant dose of 100 mg/kg, whilst it was lower with elective high-frequency ventilation at time of intubation, instead of conventional ventilation.
CONCLUSIONS: When optimizing surfactant replacement therapy and its cost-benefit ratio, pharmacokinetics and clinical variables associated with need of redosing should be taken into account.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21153401     DOI: 10.1007/s00134-010-2091-2

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  32 in total

1.  First intention high-frequency oscillation with early lung volume optimization improves pulmonary outcome in very low birth weight infants with respiratory distress syndrome.

Authors:  P C Rimensberger; M Beghetti; S Hanquinet; M Berner
Journal:  Pediatrics       Date:  2000-06       Impact factor: 7.124

2.  Single- versus multiple-dose surfactant replacement therapy in neonates of 30 to 36 weeks' gestation with respiratory distress syndrome.

Authors:  M S Dunn; A T Shennan; F Possmayer
Journal:  Pediatrics       Date:  1990-10       Impact factor: 7.124

3.  European consensus guidelines on the management of neonatal respiratory distress syndrome.

Authors:  David Sweet; Giulio Bevilacqua; Virgilio Carnielli; Gorm Greisen; Richard Plavka; Ola Didrik Saugstad; Umberto Simeoni; Christian P Speer; Adolf Valls-I-Soler; Henry Halliday
Journal:  J Perinat Med       Date:  2007       Impact factor: 1.901

Review 4.  Principles of surfactant replacement.

Authors:  B Robertson; H L Halliday
Journal:  Biochim Biophys Acta       Date:  1998-11-19

5.  Porcine surfactant replacement therapy in newborns of 25-31 weeks' gestation: a randomized, multicentre trial of prophylaxis versus rescue with multiple low doses. The French Collaborative Multicentre Study Group.

Authors:  H Walti; J Paris-Llado; G Bréart; M Couchard
Journal:  Acta Paediatr       Date:  1995-08       Impact factor: 2.299

6.  A prospective randomized comparison of conventional mechanical ventilation and very early high frequency oscillatory ventilation in extremely premature newborns with respiratory distress syndrome.

Authors:  R Plavka; P Kopecký; V Sebron; P Svihovec; B Zlatohlávková; V Janus
Journal:  Intensive Care Med       Date:  1999-01       Impact factor: 17.440

7.  High-versus low-threshold surfactant retreatment for neonatal respiratory distress syndrome.

Authors:  J Kattwinkel; B T Bloom; P Delmore; C Glick; D Brown; S Lopez; L Willett; E A Egan; M Conaway; J Patrie
Journal:  Pediatrics       Date:  2000-08       Impact factor: 7.124

8.  Surfactant replacement in neonates with early chronic lung disease.

Authors:  P B Pandit; M S Dunn; E N Kelly; M Perlman
Journal:  Pediatrics       Date:  1995-06       Impact factor: 7.124

9.  Surfactant-replacement therapy for respiratory distress in the preterm and term neonate.

Authors:  William A Engle
Journal:  Pediatrics       Date:  2008-02       Impact factor: 7.124

10.  Double-blind, randomized trial of one versus three prophylactic doses of synthetic surfactant in 826 neonates weighing 700 to 1100 grams: effects on mortality rate. American Exosurf Neonatal Study Groups I and IIa.

Authors:  A Corbet; J Gerdes; W Long; E Avila; A Puri; A Rosenberg; K Edwards; L Cook
Journal:  J Pediatr       Date:  1995-06       Impact factor: 4.406

View more
  10 in total

Review 1.  The Value of Lung Ultrasound Score in Neonatology.

Authors:  Haifeng Zong; Zhifeng Huang; Jie Zhao; Bingchun Lin; Yongping Fu; Yanqing Lin; Peng Huang; Hongyan Sun; Chuanzhong Yang
Journal:  Front Pediatr       Date:  2022-05-11       Impact factor: 3.569

Review 2.  Year in review in Intensive Care Medicine 2011: III. ARDS and ECMO, weaning, mechanical ventilation, noninvasive ventilation, pediatrics and miscellanea.

Authors:  Massimo Antonelli; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J Randall Curtis; Daniel De Backer; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2012-02-14       Impact factor: 17.440

3.  In vivo effect of pneumonia on surfactant disaturated-phosphatidylcholine kinetics in newborn infants.

Authors:  Maddalena Facco; Matteo Nespeca; Manuela Simonato; Ilena Isak; Giovanna Verlato; Gianluca Ciambra; Chiara Giorgetti; Virgilio P Carnielli; Paola E Cogo
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

4.  Porcine vs bovine surfactant therapy for preterm neonates with RDS: systematic review with biological plausibility and pragmatic meta-analysis of respiratory outcomes.

Authors:  Ascanio Tridente; Lucia De Martino; Daniele De Luca
Journal:  Respir Res       Date:  2019-02-06

5.  Porcine versus bovine surfactant therapy for RDS in preterm neonates: pragmatic meta-analysis and review of physiopathological plausibility of the effects on extra-pulmonary outcomes.

Authors:  Silvia Foligno; Daniele De Luca
Journal:  Respir Res       Date:  2020-01-07

6.  Surfactant lung delivery with LISA and InSurE in adult rabbits with respiratory distress.

Authors:  Francesca Ricci; Ilia Bresesti; Paola Azzurra Maria LaVerde; Fabrizio Salomone; Costanza Casiraghi; Arianna Mersanne; Matteo Storti; Chiara Catozzi; Laura Tigli; Riccardo Zecchi; Pietro Franceschi; Xabier Murgia; Manuela Simonato; Paola Cogo; Virgilio Carnielli; Gianluca Lista
Journal:  Pediatr Res       Date:  2021-01-15       Impact factor: 3.756

7.  Early surfactant replacement guided by lung ultrasound in preterm newborns with RDS: the ULTRASURF randomised controlled trial.

Authors:  Javier Rodriguez-Fanjul; I Jordan; M Balaguer; A Batista-Muñoz; M Ramon; S Bobillo-Perez
Journal:  Eur J Pediatr       Date:  2020-07-24       Impact factor: 3.183

8.  Minimally invasive surfactant therapy versus InSurE in preterm neonates of 28 to 34 weeks with respiratory distress syndrome on non-invasive positive pressure ventilation-a randomized controlled trial.

Authors:  Bhupendra Kumar Gupta; Anindya Kumar Saha; Suchandra Mukherjee; Bijan Saha
Journal:  Eur J Pediatr       Date:  2020-05-27       Impact factor: 3.183

9.  RETREATMENT WITH SURFACTANT IN VERY LOW BIRTH WEIGHT PRETERM INFANTS: RISK PREDICTORS AND THEIR INFLUENCE ON NEONATAL OUTCOMES.

Authors:  Walusa Assad Gonçalves Ferri; Adriana Carnevale da Silva; Eliana Motta Fernandes Sacramento; Cristina Calixto; Davi Casale Aragon; Jamil Pedro de Siqueira Caldas
Journal:  Rev Paul Pediatr       Date:  2020-11-16

Review 10.  Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps.

Authors:  Daniele De Luca; Paola Cogo; Martin C Kneyber; Paolo Biban; Malcolm Grace Semple; Jesus Perez-Gil; Giorgio Conti; Pierre Tissieres; Peter C Rimensberger
Journal:  Crit Care       Date:  2021-02-22       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.